Stoke Therapeutics Down Over 16%, on Pace for Largest Percent Decrease Since February 2024 -- Data Talk

Dow Jones11-04

Stoke Therapeutics, Inc. (STOK) is currently at $25.02, down $5.02 or 16.69%

 

--Would be lowest close since Oct. 2, 2025, when it closed at $24.82

--On pace for largest percent decrease since Feb. 13, 2024, when it fell 17.27%

--Currently down four of the past five days

--Currently down two consecutive days; down 21.06% over this period

--Worst two day stretch since the two days ending July 26, 2023, when it fell 37.04%

--Up 126.88% year-to-date; on pace for best year on record (Based on available data back to June 19, 2019)

--Down 64.15% from its all-time closing high of $69.81 on Jan. 19, 2021

--Up 91.03% from 52 weeks ago (Nov. 4, 2024), when it closed at $13.10

--Down 29.71% from its 52-week closing high of $35.60 on Oct. 15, 2025

--Up 324.15% from its 52-week closing low of $5.90 on April 8, 2025

--Traded as low as $24.50; lowest intraday level since Oct. 2, 2025, when it hit $23.56

--Down 18.44% at today's intraday low; largest intraday percent decrease since Jan. 7, 2025, when it fell as much as 19.42%

 

All data as of 2:30:06 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 03, 2025 14:33 ET (19:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment